Combining radiation therapy and androgen deprivation for localized prostate cancer- a critical review

Current Oncology

Volumn 17, Issue 5, 2010, Pages 28-38

  Dal, A ^a   Cury, F L ^a   Souhami, L ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

Androgen deprivation therapy; Combined treatment; Hormonal therapy; Prostate cancer; Radiotherapy

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; CYPROTERONE; FLUTAMIDE; GOSERELIN;

ANDROGEN DEPRIVATION THERAPY; ANEMIA; ARTICLE; BONE DEMINERALIZATION; CANCER ADJUVANT THERAPY; CANCER LOCALIZATION; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; FATIGUE; FOLLOW UP; GYNECOMASTIA; HIGH RISK PATIENT; HOT FLUSH; HUMAN; METABOLIC DISORDER; MYALGIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROSTATE CANCER; PROSTATECTOMY; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RANDOMIZED CONTROLLED TRIAL; SEXUAL DYSFUNCTION; SURVIVAL RATE; TREATMENT DURATION;

EID: 78149439533     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: None     Document Type: Article

References (78)

1. Haas GP, Delongchamps N, Brawley OW, Wang CY, de la Roza G. The worldwide epidemiology of prostate cancer: perspectives from autopsy studies. Can J Urol 2008;15:3866-71.
2. Pasteau O. Traitement du cancer de la prostate par le radium. Rev Mal Nutr 1911:303-7.
3. Kuban DA, Thames HD, Levy LB, et al. Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the psa era. Int J Radiat Oncol Biol Phys 2003;57:915-28.
4. Shipley WU, Thames HD, Sandler HM, et al. Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis. JAMA 1999;281:1598-604.
5. Zagars GK, Pollack A, von Eschenbach AC. Prognostic factors for clinically localized prostate carcinoma: analysis of 938 patients irradiated in the prostate specific antigen era. Cancer 1997;79:1370-80.
6. Peters LJ. The estro Regaud lecture. Inherent radiosensitivity of tumor and normal tissue cells as a predictor of human tumor response. Radiother Oncol 1990;17:177-90.
7. D'Amico AV, Matelski H, O'Leary M, Sussman B. Prostatespecific antigen-producing cells in the bone marrow of a patient with early-stage prostate cancer. Urology 1997;49:279-82.
8. Huggins C, Hodges CV. Studies on prostatic cancer: i. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol 2002;168:9-12.
9. Nesbit RM, Plumb RT. Prostatic carcinoma, follow-up on 795 patients treated prior to endocrine era and comparison of survival rates between these and patients treated by endocrine therapy. Surgery 1946;20:263-72.
10. de Voogt HJ, Pavone-Macaluso M, Smith PH, de Pauw M, Suciu S. Lessons from phase iii-trials on the hormonal treatment of prostatic cancer. i: Results of eortc-trials 30761 and 30762. Prog Clin Biol Res 1988;260:111-17.
11. Management of advanced cancer of prostate and bladder. Proceedings of a symposium on the tenth anniversary of eortc, Leeds, England, October 3rd, 1986 and the Fifth Course in Urological Oncology, Erice, Sicily, November 28-December 4th, 1986. Prog Clin Biol Res 1988;260:1-658.
12. Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 2000;355:1491-8.
13. Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients. Lancet 1995;346:265-9.
14. Zagars GK, Johnson DE, von Eschenbach AC, Hussey DH. Adjuvant estrogen following radiation therapy for stage C adenocarcinoma of the prostate: long-term results of a prospective randomized study. Int J Radiat Oncol Biol Phys 1988;14:1085-91.
15. Lamb DS, Denham JW, Mameghan H, et al. Acceptability of short term neo-adjuvant androgen deprivation in patients with locally advanced prostate cancer. Radiother Oncol 2003;68:255-67.
16. Tyrrell CJ, Payne H, See WA, et al. Bicalutamide ("Casodex") 150 mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: results from the randomised Early Prostate Cancer Programme. Radiother Oncol 2005;76:4-10.
17. See WA, Tyrrell CJ. The addition of bicalutamide 150 mg to radiotherapy significantly improves overall survival in men with locally advanced prostate cancer. J Cancer Res Clin Oncol 2006;132(suppl 1):S7-16.
18. Lukka H, Warde P, Pickles T, Morton G, Brundage M, Souhami L. Controversies in prostate cancer radiotherapy: consensus development. Can J Urol 2001;8:1314-22.
19. Zietman AL, Prince EA, Nakfoor BM, Park JJ. Androgen deprivation and radiation therapy: sequencing studies using the Shionogi in vivo tumor system. Int J Radiat Oncol Biol Phys 1997;38:1067-70.
20. Zietman AL, Prince EA, Nakfoor BM, Shipley WU. Neoadjuvant androgen suppression with radiation in the management of locally advanced adenocarcinoma of the prostate: experimental and clinical results. Urology 1997;49:74-83.
21. Kaminski JM, Hanlon AL, Joon DL, Meistrich M, Hachem P, Pollack A. Effect of sequencing of androgen deprivation and radiotherapy on prostate cancer growth. Int J Radiat Oncol Biol Phys 2003;57:24-8.
22. Stewart GD, Ross JA, McLaren DB, Parker CC, Habib FK, Riddick AC. The relevance of a hypoxic tumour microenvironment in prostate cancer. BJU Int 2010;105:8-13.
23. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307:58-62.
24. Folkman J. Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med 1995;333:1757-63.
25. Fukumura D, Jain RK. Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization. Microvasc Res 2007;74:72-84.
26. Joseph IB, Isaacs JT. Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgenresponsive prostatic cancers. Cancer Res 1997;57:1054-7.
27. Joseph IB, Nelson JB, Denmeade SR, Isaacs JT. Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue. Clin Cancer Res 1997;3:2507-11.
28. Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 1993;143:401-9.
29. Borre M, Offersen BV, Nerstrom B, Overgaard J. Microvessel density predicts survival in prostate cancer patients subjected to watchful waiting. Br J Cancer 1998;78:940-4.
30. Mucci LA, Powolny A, Giovannucci E, et al. Prospective study of prostate tumor angiogenesis and cancer-specific mortality in the health professionals follow-up study. J Clin Oncol 2009;27:5627-33.
31. Okihara K, Watanabe H, Kojima M. Kinetic study of tumor blood flow in prostatic cancer using power Doppler imaging. Ultrasound Med Biol 1999;25:89-94.
32. Huang SF, Chang RF, Moon WK, Lee YH, Chen DR, Suri JS. Analysis of tumor vascularity using three-dimensional power Doppler ultrasound images. IEEE Trans Med Imaging 2008;27:320-30.
33. Milosevic M, Chung P, Parker C, et al. Androgen withdrawal in patients reduces prostate cancer hypoxia: implications for disease progression and radiation response. Cancer Res 2007;67:6022-5.
34. Milosevic M, Chung P, Toi A, et al. Androgen deprivation reduces hypoxia in human prostate cancer. Int J Radiat Oncol Biol Phys 2006;66(suppl 3):S12.
35. Isaacs JT, Lundmo PI, Berges R, Martikainen P, Kyprianou N, English HF. Androgen regulation of programmed death of normal and malignant prostatic cells. J Androl 1992;13:457-64.
36. Roden AC, Moser MT, Tri SD, et al. Augmentation of T cell levels and responses induced by androgen deprivation. J Immunol 2004;173:6098-108.
37. Cooperberg MR, Broering JM, Litwin MS, et al. The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (capsure), a national disease registry. J Urol 2004;171:1393-401
38. McGowan D, Hunt D, Jones C, et al. Short-term endocrine therapy prior to and during radiation therapy improves overall survival in patients with T1b-T2b adenocarcinoma of the prostate and psa ≤ 20: initial results of rtog 94-08. Int J Radiat Oncol Biol Phys 2010;77:1.
39. Pilepich MV, Winter K, John MJ, et al. Phase iii radiation therapy oncology group (rtog) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001;50:1243-52.
40. Roach M 3rd, Bae K, Speight J, et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of rtog 8610. J Clin Oncol 2008;26:585-91.
41. Laverdiere J, Nabid A, De Bedoya LD, et al. The efficacy and sequencing of a short course of androgen suppression on freedom from biochemical failure when administered with radiation therapy for T2-T3 prostate cancer. J Urol 2004;171:1137-40.
42. D'Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW. 6-Month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 2004;292:821-7.
43. D'Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA 2008;299:289-95.
44. Denham JW, Steigler A, Lamb DS, et al. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol 2005;6:841-50.
45. Nguyen PL, Chen MH, Beard CJ, et al. Radiation with or without 6 months of androgen suppression therapy in intermediate- and high-risk clinically localized prostate cancer: a postrandomization analysis by risk group. Int J Radiat Oncol Biol Phys 2009;77:1046-52.
46. Roach M 3rd, Hanks G, Thames H Jr, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the rtog-astro Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006;65:965-74.
47. Oefelein MG. Time to normalization of serum testosterone after 3-month luteinizing hormone-releasing hormone agonist administered in the neoadjuvant setting: implications for dosing schedule and neoadjuvant study consideration. J Urol 1998;160:1685-8.
48. Padula GD, Zelefsky MJ, Venkatraman ES, et al. Normalization of serum testosterone levels in patients treated with neoadjuvant hormonal therapy and three-dimensional conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2002;52:439-43.
49. Crook J, Ludgate C, Malone S, et al. Report of a multicenter Canadian phase iii randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2004;60:15-23.
50. Crook J, Ludgate C, Malone S, et al. Final report of multicenter Canadian phase iii randomized trial of 3 versus 8 months of neoadjuvant androgen deprivation therapy before conventionaldose radiotherapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2009;73:327-33.
51. Alexander A, Crook J, Jones S, et al. Is biochemical response more important than duration of neoadjuvant hormone therapy before radiotherapy for clinically localized prostate cancer? an analysis of the 3- versus 8-month randomized trial. Int J Radiat Oncol Biol Phys 2010;76:23-30.
52. Pilepich MV, Caplan R, Byhardt RW, et al. Phase iii trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31. J Clin Oncol 1997;15:1013-21.
53. Pilepich MV, Winter K, Lawton CA, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma- long-term results of phase iii rtog 85-31. Int J Radiat Oncol Biol Phys 2005;61:1285-90.
54. Bolla M, Gonzalez D, Warde P, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997;337:295-300.
55. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an eortc study): a phase iii randomised trial. Lancet 2002;360:103-6.
56. Hanks GE, Pajak TF, Porter A, et al. Phase iii trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 2003;21:3972-8.
57. Horwitz EM, Bae K, Hanks GE, et al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase iii trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 2008;26:2497-504.
58. Souhami L, Bae K, Pilepich M, Sandler H. Impact of the duration of adjuvant hormonal therapy in patients with locally advanced prostate cancer treated with radiotherapy: a secondary analysis of rtog 85-31. J Clin Oncol 2009;27:2137-43.
59. Pollack A, Salem N, Ashoori F, et al. Lack of prostate cancer radiosensitization by androgen deprivation. Int J Radiat Oncol Biol Phys 2001;51:1002-7.
60. Bolla M, de Reijke TM, Van Tienhoven G, et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 2009;360:2516-27.
61. D'Amico AV, Denham JW, Bolla M, et al. Short- vs long-term androgen suppression plus external beam radiation therapy and survival in men of advanced age with node-negative high-risk adenocarcinoma of the prostate. Cancer 2007;109:2004-10.
62. Haworth A, Kearvell R, Greer PB, et al. Assuring high quality treatment delivery in clinical trials-results from the Trans- Tasman Radiation Oncology Group (trog) study 03.04 "radar" set-up accuracy study. Radiother Oncol 2009;90:299-306.
63. Kuban DA, Tucker SL, Dong L, et al. Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 2008;70:67-74.
64. Peeters ST, Heemsbergen WD, Koper PC, et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase iii trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 2006;24:1990-6.
65. Sathya JR, Davis IR, Julian JA, et al. Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate. J Clin Oncol 2005;23:1192-9.
66. Dearnaley DP, Sydes MR, Graham JD, et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the mrc RT01 randomised controlled trial. Lancet Oncol 2007;8:475-87.
67. Zietman AL, DeSilvio ML, Slater JD, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 2005;294:1233-9.
68. Zietman AL. Correction: inaccurate analysis and results in a study of radiation therapy in adenocarcinoma of the prostate. JAMA 2008;299:898-9.
69. Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA 2005;294:238-44.
70. Alibhai SM, Gogov S, Allibhai Z. Long-term side effects of androgen deprivation therapy in men with non-metastatic prostate cancer: a systematic literature review. Crit Rev Oncol Hematol 2006;60:201-15.
71. Greenspan SL, Coates P, Sereika SM, Nelson JB, Trump DL, Resnick NM. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab 2005;90:6410-17.
72. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006;24:4448-56.
73. Saigal CS, Gore JL, Krupski TL, Hanley J, Schonlau M, Litwin MS. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 2007;110:1493-500.
74. Tsai HK, D'Amico AV, Sadetsky N, Chen MH, Carroll PR. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst 2007;99:1516-24.
75. Alibhai SM, Duong-Hua M, Sutradhar R, et al. Impact of androgen deprivation therapy on cardiovascular disease and diabetes. J Clin Oncol 2009;27:3452-8.
76. D'Amico AV, Denham JW, Crook J, et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol 2007;25:2420-5.
77. Nanda A, Chen MH, Braccioforte MH, Moran BJ, D'Amico AV. Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction. JAMA 2009;302:866-73.
78. Efstathiou JA, Bae K, Shipley WU, et al. Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: rtog 85-31. J Clin Oncol 2009;27:92-9.